KPMA backlashes against government's tax incentive reduction.

Published: 2002-10-01 06:59:00

Updated: 2002-10-01 06:59:00

The KPMA sensitively concerned about the government's tax incentive policy of intending to reduce over the new drug R&D, and earnestly urged them to withdraw its policy.

The KPMA presented a recommendation letter to the Ministry of Finance and Economy on Sept. 19 to reconsider the revised bill...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK